Technology evaluation: HSPPC-96, antigenics.
Antigenics is developing HSPPC-96, a vaccine based on heat shock protein for the potential treatment of various cancer indications. The compound is currently undergoing phase III clinical trials for renal cell carcinoma and melanoma.
Minev
Boris R
BR
Cancer Center, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0063, USA. bminev@ucsd.edu
D000818:Animals; D015703:Antigens, CD / Q000378:metabolism; D019496:Cancer Vaccines / Q000737:chemistry / Q000276:immunology / Q000378:metabolism* / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D006360:Heat-Shock Proteins / Q000737:chemistry / Q000276:immunology* / Q000378:metabolism*; D006801:Humans; D026503:Low Density Lipoprotein Receptor-Related Protein-1; D009369:Neoplasms / Q000188:drug therapy*; D013329:Structure-Activity Relationship
D015703:Antigens, CD; D019496:Cancer Vaccines; D006360:Heat-Shock Proteins; C475476:LRP1 protein, human; D026503:Low Density Lipoprotein Receptor-Related Protein-1